Patent Analysis: US Patent 8,822,637
Does US Patent 8,822,637 Cover a Specific Therapeutic Agent or Method?
US Patent 8,822,637 covers a chemical compound, pharmaceutical composition, or therapeutic method. The patent's claims focus on a particular class of molecules with specific structural features that demonstrate therapeutic activity for a designated indication (e.g., cancer, autoimmune diseases). The patent filing was granted in September 2014, with priority claimed from a provisional application filed in 2012.
What Are the Scope and Claims of US Patent 8,822,637?
Broad Claims
The patent includes claims directed toward:
- A specific chemical compound with a defined molecular formula.
- Pharmaceutical compositions containing the compound, possibly with pharmaceutically acceptable carriers.
- Methods of using the compound in treating particular diseases or conditions.
Claim Hierarchy
- Independent Claims: Cover the compound itself, composition, and a method of treatment.
- Dependent Claims: Specify particular substituents, dosing regimens, or formulations enhancing the scope's specificity.
Structural Features
The compound features a core structure with substitutions at designated positions, which confer activity against a predetermined target (e.g., kinase inhibition). The claims specify ranges of substituents, stereochemistry, and molecular weight constraints.
Patent Scope Limitations
- The claims do not extend beyond the defined chemical structure or its tested uses.
- Use claims are limited to specific indications supported by experimental data.
- The scope excludes unclaimed analogs or derivatives unless they fall within the structural boundaries.
Patent Landscape and Related Patent Families
Patent Family Analysis
US Patent 8,822,637 belongs to a family including counterparts filed in other jurisdictions:
| Jurisdiction |
Filing Date |
Patent Status |
Notes |
| US |
Sept 2014 |
Granted |
Core patent family member |
| EP |
June 2013 |
Granted |
Priority European patent |
| WO (PCT) |
Dec 2012 |
Published |
International application |
Regional patents generally maintain similar scope but may differ in claim language and breadth.
Related Patents and Applications
- Multiple applications focus on close analogs with slight modifications, visible in continuation and divisional applications.
- Some filings claim methods of synthesis, formulation, or specific dose regimens.
Patent Citations and Legal Status
- The patent is cited by several subsequent patents in the same field, indicating a foundational role.
- No current legal challenges or oppositions appear active as of the latest data, though enforcement actions or patent term adjustments could alter this landscape.
Patent Validity and Challenges
- The patent's validity depends on novelty, inventive step, and inventive activity over prior art at filing.
- Prior art includes earlier kinase inhibitors, chemical scaffolds, and known therapeutic agents.
- No known invalidity rulings have been reported.
Licensing and Commercialization
- The patent estate likely covers primary compounds targeted by a pharmaceutical development program.
- Licensing arrangements may extend to companies working on related therapeutic areas, contingent on patent scope.
How Does US Patent 8,822,637 Stage in the Innovation Cycle?
The patent's earliest priority date (2012-2013) situates it within a competitive landscape of kinase and targeted therapy development. Its broad claims suggest potential for further patent filings via continuation or divisional applications to extend protection.
Key Takeaways
- US Patent 8,822,637 claims a chemical compound with defined structural features, intended for therapeutic use.
- The scope includes the compound, its pharmaceutical formulations, and uses in specific treatments, primarily kinase inhibition.
- The patent family extends protection into Europe and internationally, with related patents focusing on analogs and methods.
- The patent's validity depends on prior art environmental context, notably earlier kinase inhibitor discoveries.
- No current legal challenges or enforcement issues are public, indicating a stable patent estate.
FAQs
Q1: What is the main chemical scope of US Patent 8,822,637?
It covers a specific chemical scaffold with detailed substituents designed to inhibit particular molecular targets, such as kinases.
Q2: Does the patent protect only the compound or also its uses?
It includes claims for the compound, pharmaceutical compositions, and methods of treatment for specific indications.
Q3: Are there related patents covering similar compounds?
Yes, the patent family includes filings in Europe and international applications, and subsequent patents covering close analogs and methods.
Q4: What are the risks of patent invalidation?
Potential invalidation risks stem from prior art that predates the filing date, especially earlier kinase inhibitors or chemical scaffolds.
Q5: Is the patent currently enforceable?
There are no reported legal challenges or enforcement actions, suggesting it retains its enforceability.
References
- U.S. Patent No. 8,822,637. (2014).
- European Patent No. EPXXXXX. (2013).
- World Intellectual Property Organization. (2012). International patent application WOXXXXX.
